Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN DDRiver Bladder
jRCT2071240048Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of avelumab and tuvusertib in transitional cell carcinoma (TCC), sponsored by Merck KGaA. Primary endpoint: Confirmed objective response. Started Aug 2024; status: active, not recruiting.
02
Drugs
avelumabtuvusertib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2071240048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240048.